Large cell carcinoma of the lung natural history: Difference between revisions
Jump to navigation
Jump to search
| (7 intermediate revisions by 3 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes. | If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes. Large cell carcinoma of the lung is a locally aggressive tumor. Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years. Common sites of metastasis include [[adrenal gland]], [[Bone tumors|bone]], [[brain]], and [[liver]]. Complications of large cell carcinoma of the lung, include: [[respiratory failure|acute respiratory failure]], [[pleural effusion|malignant pleural effusion]], [[metastases]], and [[pneumonia]]. Features associated with worse prognosis are presence of lymphatic invasion, location of lesion, gene expression profile, performance status, presence of satellite lesions, and presence of regional or distant metastases. Prognosis is generally regarded as poor. | ||
==Natural History== | ==Natural History== | ||
*If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes.<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref> | *If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to [[chest wall]] and adjacent [[lymph nodes]].<ref name="pmid17356101">{{cite journal |vauthors=Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E |title=Prognosis of lung cancer patients with life-threatening complications |journal=Chest |volume=131 |issue=3 |pages=840–6 |year=2007 |pmid=17356101 |doi=10.1378/chest.06-2244 |url=}}</ref> | ||
*Large cell carcinoma of the lung is a locally aggressive tumor. | *Large cell carcinoma of the lung is a locally aggressive tumor. | ||
*Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. | *Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. | ||
*Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years. | *Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years.<ref name="pmid17356101" /> | ||
*Common sites of metastasis include [[adrenal gland]], [[Bone tumors|bone]], [[brain]], and [[liver]] | *Common sites of metastasis include [[adrenal gland]], [[Bone tumors|bone]], [[brain]], and [[liver]] | ||
| Line 24: | Line 24: | ||
==Prognosis== | ==Prognosis== | ||
*Prognosis of large cell carcinoma of the lung is generally regarded as poor | *Prognosis of large cell carcinoma of the lung is generally regarded as poor | ||
*Features associated with worse prognosis in large cell carcinoma of the lung | *Features associated with worse prognosis in large cell carcinoma of the lung include:<ref name="pmid21566535">{{cite journal |vauthors=Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, DeCamp MM |title=Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? |journal=J Thorac Oncol |volume=6 |issue=6 |pages=1050–8 |year=2011 |pmid=21566535 |doi=10.1097/JTO.0b013e318217b6f8 |url=}}</ref> | ||
:*Histologic subtype of large cell neuroendocrine tumor | :*Histologic subtype of large cell neuroendocrine tumor | ||
:*Presence of lymphatic invasion | :*Presence of lymphatic invasion | ||
| Line 31: | Line 31: | ||
:*Presence of satellite lesions | :*Presence of satellite lesions | ||
:*Presence of regional or distant metastases | :*Presence of regional or distant metastases | ||
* 5 year median survival rate depends on stage of resection:<ref name="pmid16382115">{{cite journal |vauthors=Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K |title=Neuroendocrine neoplasms of the lung: a prognostic spectrum |journal=J. Clin. Oncol. |volume=24 |issue=1 |pages=70–6 |date=January 2006 |pmid=16382115 |doi=10.1200/JCO.2005.04.1202 |url=}}</ref><ref name="pmid9706973">{{cite journal |vauthors=Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN |title=Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid |journal=Am. J. Surg. Pathol. |volume=22 |issue=8 |pages=934–44 |date=August 1998 |pmid=9706973 |doi= |url=}}</ref> | |||
** Resectable stage 1- 33% | |||
** Resectable stage 2- 23% | |||
** Resectable stage 3- 8% | |||
** Resectable stage 4- 9.2-12.6 (months) | |||
==References== | ==References== | ||
| Line 40: | Line 45: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Pulmonology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 13:19, 21 March 2018
|
Large Cell Carcinoma of the Lung Microchapters |
|
Differentiating Large Cell Carcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Large cell carcinoma of the lung natural history On the Web |
|
American Roentgen Ray Society Images of Large cell carcinoma of the lung natural history |
|
Large cell carcinoma of the lung natural history in the news |
|
Directions to Hospitals Treating Large cell carcinoma of the lung |
|
Risk calculators and risk factors for Large cell carcinoma of the lung natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes. Large cell carcinoma of the lung is a locally aggressive tumor. Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years. Common sites of metastasis include adrenal gland, bone, brain, and liver. Complications of large cell carcinoma of the lung, include: acute respiratory failure, malignant pleural effusion, metastases, and pneumonia. Features associated with worse prognosis are presence of lymphatic invasion, location of lesion, gene expression profile, performance status, presence of satellite lesions, and presence of regional or distant metastases. Prognosis is generally regarded as poor.
Natural History
- If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes.[1]
- Large cell carcinoma of the lung is a locally aggressive tumor.
- Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer.
- Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years.[1]
- Common sites of metastasis include adrenal gland, bone, brain, and liver
Complications
- Complications of large cell carcinoma of the lung, include:
Prognosis
- Prognosis of large cell carcinoma of the lung is generally regarded as poor
- Features associated with worse prognosis in large cell carcinoma of the lung include:[2]
- Histologic subtype of large cell neuroendocrine tumor
- Presence of lymphatic invasion
- Location of lesion
- Poor performance status
- Presence of satellite lesions
- Presence of regional or distant metastases
- 5 year median survival rate depends on stage of resection:[3][4]
- Resectable stage 1- 33%
- Resectable stage 2- 23%
- Resectable stage 3- 8%
- Resectable stage 4- 9.2-12.6 (months)
References
- ↑ 1.0 1.1 Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E (2007). "Prognosis of lung cancer patients with life-threatening complications". Chest. 131 (3): 840–6. doi:10.1378/chest.06-2244. PMID 17356101.
- ↑ Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS, DeCamp MM (2011). "Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?". J Thorac Oncol. 6 (6): 1050–8. doi:10.1097/JTO.0b013e318217b6f8. PMID 21566535.
- ↑ Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K, Nagai K (January 2006). "Neuroendocrine neoplasms of the lung: a prognostic spectrum". J. Clin. Oncol. 24 (1): 70–6. doi:10.1200/JCO.2005.04.1202. PMID 16382115.
- ↑ Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN (August 1998). "Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid". Am. J. Surg. Pathol. 22 (8): 934–44. PMID 9706973.